CHRS Coherus BioSciences Inc.

14.47
-0.24  -2%
Previous Close 14.71
Open 14.72
Price To Book -25.84
Market Cap 1003330946
Shares 69,338,697
Volume 85,122
Short Ratio
Av. Daily Volume 814,308

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Rheumatoid arthritis
Phase 2b data released June 2016
CHS-131
Relapsing remitting multiple sclerosis (RRMS)
Phase 3 top-line data met endpoints August 2016. BLA filing due late 2019.
CHS-1420
Psoriasis
Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues
CHS-0214
Psoriasis
FDA approval announced November 2, 2018.
CHS-1701
Pegfilgrastim biosimilar

Latest News

  1. Coherus BioSciences Announces New Employment Inducement Grants
  2. Coherus (CHRS) Catches Eye: Stock Jumps 6.9%
  3. Why Sony, AMC Entertainment Holdings, and Coherus BioSciences Jumped Today
  4. Here's Why Coherus BioSciences Popped Today
  5. Read This Before Buying Coherus BioSciences, Inc. (NASDAQ:CHRS) Shares
  6. Coherus BioSciences Announces Unaudited First Quarter 2019 UDENYCA™ Net Sales
  7. Coherus BioSciences to Report First Quarter Financial Results on May 9th
  8. Coherus BioSciences Management to Present at H.C. Wainwright & Co. Global Life Sciences Conference
  9. See what the IHS Markit Score report has to say about Coherus BioSciences Inc.
  10. Coherus BioSciences Appoints Thomas Fitzpatrick Chief Legal Officer
  11. Edited Transcript of CHRS earnings conference call or presentation 28-Feb-19 9:30pm GMT
  12. New Research: Key Drivers of Growth for American Tower Corporation (REIT), Lowe's Companies, Mimecast, Live Nation Entertainment, Intercept Pharmaceuticals, and Coherus BioSciences — Factors of Influence, Major Initiatives and Sustained Production
  13. Coherus BioSciences Inc (CHRS) Q4 2018 Earnings Conference Call Transcript
  14. Coherus BioSciences Reports Fourth Quarter and Full Year 2018 Financial Results
  15. Coherus BioSciences Management to Present at Two Investor Healthcare Conferences in March
  16. Coherus BioSciences to Report Fourth Quarter and Full Year 2018 Financial Results on February 28th